Display options
Share it on

Med J Islam Repub Iran. 2016 Feb 13;30:326. eCollection 2016.

Cost effectiveness of type 2 diabetes screening: A systematic review.

Medical journal of the Islamic Republic of Iran

Behzad Najafi, Farshad Farzadfar, Hossein Ghaderi, Mohammad Hadian

Affiliations

  1. Assistant Professor, Department of Health Economics, School of Health Management and Information Science, Iran University of Medical Sciences, Tehran, Iran. [email protected].
  2. Non-communicable Diseases Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, Iran. [email protected].
  3. Assistant Professor, Department of Health Economics, School of Health Management and Information Science, Iran University of Medical Sciences, Tehran, Iran. [email protected].
  4. Assistant Professor, Department of Health Economics, School of Health Management and Information Science, Iran University of Medical Sciences, Tehran, Iran. [email protected].

PMID: 27390696 PMCID: PMC4898846

Abstract

BACKGROUND: Although studies reported diabetes mellitus screening cost effective, the mass screening for type2 diabetes remains controversial. In this study we reviewed the recently evidence about the cost effectiveness of mass screening systematically.

METHODS: We reviewed the MEDLINE, Scopus, Web of Science (WOS), and Cochrane library databases by MeSH terms to identify relevant studies from 2000 to 2013. We had 4 inclusion and 6 exclusion criteria and used the Drummond's checklist for appraising the quality of studies.

RESULTS: The initial search yielded 358 potentially related studies from selected databases. 6 studies met our inclusion and exclusion criteria and included in final review. 3 and 2 of them were conducted in Europe and America and only one of them in Asia. Quality-adjusted life year (QALY) was the main outcome to appraise the effectiveness in the studies. Incremental cost effectiveness ratio (ICER) was computed in range from $516.33 to $126,238 per QALY in the studies.

CONCLUSION: A review of previous diabetes screening cost effectiveness analysis showed that the studies varied in some aspects but reached similar conclusions. They concluded that the screening may be cost effective, however further studies is required to support the diabetes mass screening.

Keywords: Cost effectiveness; Diabetes; Economic evaluation; Screening

References

  1. Diabetes Res Clin Pract. 2010 Jan;87(1):15-9 - PubMed
  2. Pharmacoeconomics. 2006;24(5):425-41 - PubMed
  3. Lancet. 2015 Jan 10;385(9963):117-71 - PubMed
  4. Prev Cardiol. 2003 Spring;6(2):78-84 - PubMed
  5. Diabetes Care. 2003 Jan;26 Suppl 1:S21-4 - PubMed
  6. Diabetes Care. 2004 Jan;27 Suppl 1:S11-4 - PubMed
  7. Lancet. 2010 Apr 17;375(9723):1365-74 - PubMed
  8. Appl Health Econ Health Policy. 2010;8(3):191-202 - PubMed
  9. Ann Intern Med. 2008 Jun 3;148(11):846-54 - PubMed
  10. Eff Clin Pract. 2001 Nov-Dec;4(6):271-7 - PubMed
  11. Diabetes Care. 2010 Aug;33(8):1872-94 - PubMed
  12. Diabetes Care. 1999 Jul;22(7):1116-24 - PubMed
  13. JAMA. 1998 Nov 25;280(20):1757-63 - PubMed
  14. WMJ. 2000 Jun;99(3):39-43 - PubMed
  15. Diabetes Res Clin Pract. 2001 Nov;54 Suppl 1:S37-42 - PubMed
  16. BMC Health Serv Res. 2012 Aug 16;12:253 - PubMed
  17. BMJ. 2008 May 24;336(7654):1180-5 - PubMed
  18. BMJ. 1996 Aug 3;313(7052):275-83 - PubMed
  19. Ann Intern Med. 2004 May 4;140(9):689-99 - PubMed

Publication Types